Literature DB >> 19715759

Real-time bioluminescence imaging of polycythemia vera development in mice.

Yanhong Ma1, Shuxia Zhao, Joe Zhu, Kimberly A Bettano, Xianlu Qu, C Gary Marshall, Jonathan R Young, Nancy E Kohl, Martin L Scott, Weisheng Zhang, Yuxun Wang.   

Abstract

Polycythemia vera (PV) is a myeloproliferative disorder involving hematopoietic stem cells. A recurrent somatic missense mutation in JAK2 (JAK2V617F) is thought to play a causal role in PV. Therefore, targeting Jak2 will likely provide a molecular mechanism-based therapy for PV. To facilitate the development of such new and specific therapeutics, a suitable and well-characterized preclinical animal model is essential. Although several mouse models of PV have been reported, the spatiotemporal kinetics of PV formation and progression has not been studied. To address this, we created a bone marrow transplant mouse model that co-expresses mutant Jak2 and luciferase 2 (Luc2) genes. Bioluminescent imaging (BLI) was used to visualize disease cells and analyze the kinetics of PV development in vivo. To better understand the molecular mechanism of PV, we generated mice carrying a kinase inactive mutant Jak2 (Jak2K882E), demonstrating that the PV disease was dependent on constitutive activation of the Jak2 kinase activity. We further showed that the Jak2V617F mutation caused increased stem cell renewal activity and impaired cell differentiation, which was at least in part due to deregulated transcriptional programming. The Jak2V617F-Luc2 PV mice will be a useful preclinical model to characterize novel JAK2 inhibitors for the treatment of PV.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19715759     DOI: 10.1016/j.bbadis.2009.08.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

1.  Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera.

Authors:  Manfred Kraus; Yuxun Wang; Dan Aleksandrowicz; Eric Bachman; Alexander A Szewczak; Deborah Walker; Lin Xu; Melaney Bouthillette; Kaleen M Childers; Brian Dolinski; Andrew M Haidle; Johnny Kopinja; Linda Lee; Jongwon Lim; Kevin D Little; Yanhong Ma; Anjili Mathur; Jan-Rung Mo; Erin O'Hare; Ryan D Otte; Brandon M Taoka; Wenxian Wang; Hong Yin; Anna A Zabierek; Weisheng Zhang; Shuxia Zhao; Joe Zhu; Jonathan R Young; C Gary Marshall
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

2.  In Vivo Imaging in Pharmaceutical Development and Its Impact on the 3Rs.

Authors:  Barry R Campbell; Dinko Gonzalez Trotter; Catherine D G Hines; Wenping Li; Manishkumar Patel; Weisheng Zhang; Jeffrey L Evelhoch
Journal:  ILAR J       Date:  2016-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.